Regor Therapeutics
Suzhou, China· Est.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Funding information not available
Overview
Regor Therapeutics uses AI-powered discovery to create small molecule drugs for oncology and metabolic diseases, then partners with pharma giants for development.
OncologyMetabolismImmunology
Technology Platform
rCARD (computer-accelerated rational discovery) platform integrating computational biology, structural biology, and computational chemistry for AI-driven small molecule drug discovery and optimization.
Opportunities
Major opportunity in oral GLP-1 market for obesity if RGT-075 demonstrates competitive efficacy and tolerability; additional out-licensing deals for preclinical assets in oncology and immunology.
Risk Factors
Heavy dependence on partner-led clinical development; intense competition in both obesity (oral GLP-1) and CDK inhibitor markets; platform validation requires continued successful partnerships.
Competitive Landscape
Competes with other AI-driven discovery companies (Exscientia, Recursion) and traditional metabolic disease developers; differentiation through integrated computational/experimental platform and proven out-licensing track record with major pharma.